Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-15

Clinical Trial Update: Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety and efficacy of aliskiren in children aged 6 to 17 with hypertension; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tekturna (aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-10-15